Table 2 Immune-checkpoint blockade of NK cells in hematologic malignancies[1]
Targeting Checkpoint Receptor | ICB Product | Clinical Trial | Disease | Phase | Status | Marketing Approved |
|---|---|---|---|---|---|---|
PD-1 | Pembrolizumab (MK-3475) | NCT05514990 NCT05507541 NCT05508867 NCT05493618 NCT05404945 NCT05400876 NCT05355051 NCT05313243 NCT05221645 NCT05204160 NCT05191472 NCT05180097 NCT05179603[3] | MM B lymphoma HL MM HL Lymphoma HL T lymphoma DLBCL MM MM HL HL/DLBCL | I/II II III I/II II I/II II II II II II II II | Recruiting Not yet recruiting Recruiting Not yet recruiting Recruiting Recruiting Recruiting Not yet recruiting Recruiting Recruiting Recruiting Recruiting Active, not recruiting | Keytruda, for classical HL and several solid tumors. Initial U.S. Approval: Sep. 2014 Kisplyx. Initial EU. Approval: Aug. 2016 Keytruda. Initial EU. Approval: Jul. 2015 Keytruda, for leukemia, lymphoma and solid tumors. Initial China. Approval: Jul. 2018 |
Nivolumab | NCT05385263 NCT05352828 NCT05310591 NCT05272384 NCT05255601 NCT05253495 NCT05211336 NCT05162976[3] | B lymphoma HL ALL B lymphoma HL/NHL HL/NHL B lymphoma HL | II I I/II II I/II II I I | Recruiting Recruiting Not yet recruiting Recruiting Recruiting Recruiting Suspended Recruiting | Opdualag, a combination of Nivolumab and Relatlimab, was approved for classical HL. Initial U.S. Approval: Mar. 2022 Opdivo, nivolumab injection, for intravenous use for classical HL. Initial FDA Approval: May. 2016 Opdivo for HL. Initial EU. Approval: Jun. 2015 Opdivo for leukemia and lymphoma. Initial China Approval: Aug. 2019 | |
Toripalimab (JS-001) | NCT05564806[3] | NHL | I | Not yet recruiting | Toripalimab Injection for hematologic malignancies. Initial China Approval: Dec. 2018 | |
Geptanolimab (GB226) | NCT03639181 NCT03502629 NCT03374007 | B lymphoma T lymphoma Lymphoma | II II I | Recruiting Recruiting Recruiting | Not yet | |
Nofazinlimab (CS1003) | NCT03809767 | Lymphoma | I | Active, not recruiting | Not yet | |
SCT-I10A | NCT03821363 | Lymphoma | I | Unknown status | Not yet | |
Sym021 | NCT03311412 | Lymphoma | I | Completed | Not yet | |
PD-L1 | Durvalumab (MEDI4736) | NCT05388006 NCT04688151 NCT04462328[2] | CLL PCNSL PCNSL | II I I | Recruiting Not yet recruiting Recruiting | Imfinzi, durvalumab injection, for intravenous use for solid tumors. Initial U.S. Approval: May. 2017 Imfinzi for non-small cell lung cancer. Initial U.S. Approval: Feb. 2018 Imfinzi for non-small cell lung cancer. Initial EU. Approval: Sep. 2018 Imfinzi for solid tumors and hematological malignancies. Initial China. Approval: Dec. 2019 |
Avelumab | NCT03905135 NCT04328844[2] | T lymphoma NHL | I I | Completed Recruiting | Bavencio, avelumab injection, for intravenous use for solid tumors. Initial U.S. Approval: Mar. 2017 Bavencio for neuroendocrine tumors. Initial EU. Approval: Sep. 2017 Not yet for hematologic malignancies | |
LAG-3 | Relatlimab (BMS-986016) | NCT05255601 NCT04913922 NCT04150965 NCT02061761 | HL/NHL AML MM Hematologic Neoplasms | I/II II I/II I/II | Recruiting Recruiting Recruiting Completed | Opdualag, a combination of Nivolumab and Relatlimab, was approved for metastatic melanoma. Initial U.S. Approval: Mar. 2022 Opdualag was approved for melanoma. Initial EU. Approval: Sep. 2022 Not yet for hematologic malignancies |
Fianlimab (REGN-3767) | NCT04566978 | B lymphoma | Early I | Recruiting | Not yet | |
Sym022 | NCT03311412 | Lymphoma | I | Completed | Not yet | |
KIRs | Lirilumab | NCT02599649 NCT02481297 NCT02399917 NCT01687387 NCT01592370 | MDS Leukemia Leukemia AML MM/NHL | II II II II I/II | Terminated Completed Terminated Completed Active, not recruiting | Not yet |
IPH4102 | NCT05321147 NCT03902184 NCT02593045 | PTCL T lymphoma CTCL | I II I | Recruiting Recruiting Completed | Not yet | |
IPH2101 | NCT01248455 NCT01222286 NCT01217203 NCT00999830 NCT00552396 | MM MM MM MM MM | II II I II I | Terminated Completed Completed Completed Completed | Not yet | |
NKG2A | Monalizumab | NCT02921685 NCT02557516 | Hematologic malignancies CLL | I I/II | Unknown status Terminated | Not yet |
TIM-3 | Sabatolimab (MBG-453) | NCT05367401 NCT05201066 NCT04878432 NCT04823624 NCT04812548 NCT04810611 NCT04623216 NCT04266301[2] | MDS/AML MDS MDS MDS MDS MDS AML MDS/CML | I/II II II II II I I/II III | Not yet recruiting Not yet recruiting Recruiting Not yet recruiting Active, not recruiting Recruiting Recruiting Active, not recruiting | Not yet |
Sym023 | NCT03489343 | Lymphoma | I | Completed | Not yet | |
TIGIT | Tiragolumab | NCT05315713 NCT04045028 | NHL MM/NHL | I/II I | Recruiting Recruiting | Not yet |
BMS-986207 | NCT04150965 | MM | I/II | Recruiting | Not yet |